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Abstract
Histidine-rich peptides are commonly used in recombinant protein production as purification tags, allowing the
one-step affinity separation of the His-tagged proteins from the extracellular media or cell extracts. Genetic
engineering makes feasible the post-purification His-tag removal by inserting, between the tag and the main
protein body, a target site for trans-acting proteases or a self-proteolytic peptide with regulatable activities.
However, for technical ease, His tags are often not removed and the fusion proteins eventually used in this form.
In this commentary, we revise the powerful biological properties of histidine-rich peptides as endosomolytic agents
and as architectonic tags in nanoparticle formation, for which they are exploited in drug delivery and other
nanomedical applications. These activities, generally unknown to biotechnologists, can unwillingly modulate the
functionality and biotechnological performance of recombinant proteins in which they remain trivially attached.
Affinity protein purification
Protein engineering and production, as a widely spread
methodological platform, is providing reagents for catalysis,
drugs for pharmaceutical industries and in general, instru-
ments for analytical research in structural biology, proteo-
mics, interactomics and drug design, among others. If
secreted, recombinant proteins produced in prokaryotic or
eukaryotic cell factories are found diluted in the medium,
or alternatively, they occur as minor components of extre-
mely complex macromolecular mixtures if retained inside
the cell. Therefore, they must be purified so as achieve con-
veniently high concentration and purity levels required for
stable storage and characterization or for efficient use in
biological systems or in catalysis. The identification of pep-
tide tags for single-step affinity-based purification, upon
end terminal fusion, has provided an advantageous tool
that represents a faster, easy and cost-effective alternative
to multiple-step chromatographic separations [1,2]. Protein
tagging allows the purification of virtually any protein with-
out previous knowledge of its properties or those of its
expected contaminants, since the capturing event relies on
tag’sr a t h e rt h a no np r o t e i n ’sf e a t u r e s .
Being absent in the natural target protein, affinity tags
are expected to be removed upon purification, to keep the
target protein sequence as natural as possible [3,4]. During
the upstream cloning strategies, recombinant proteins can
be designed to contain target sites for trans-acting pro-
teases [4] or alternatively, functional endoproteolytic pep-
tides [5] to remove the additional peptides. The Tobacco
Etch Virus TEV protease (TEVp) is probably the most
used agent for trans tag removal, because of its high speci-
ficity for the TEVp target site (ENLYFQ↓G) compared to
the most promiscuous behaviour of alternative enzymes
such as factor Xa, enterokinase and some picornaviridae
3C proteases [4]. On the other hand, inteins are among
the most used cis-acting tag-removal agents [6-8].
However, for technical convenience, the foreign peptide
is often not removed after purification, as for instance, the
C-position of the cleavage site in the recognition sequence
of most endoproteases makes specially difficult the com-
plete removal of C-terminal added stretches [1]. Obviously,
the modification of the primary amino acid sequence is
expected to have effects on physicochemical parameters of
the protein such as the distribution of charged amino acids
and the final conformation, and also on biological proper-
ties such as in intra- or intermolecular interactions, solubi-
lity and enzymatic activity. However, some observations
suggest that such effects might be extremely soft or even
convenient. In this context, a few additional end terminal
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or atomic interactions, leading to the correct 3D structure
determination [9]. Furthermore, the presence of purifica-
tion tags might positively affect the solubility, productivity
and proteolytic stability of recombinant proteins [10-14],
which would provide an added value to these protein seg-
ments. These observations have prompted researchers to
evaluate affinity tags not only for their usefulness as tools
for downstream but also as midstream folding-assistant
agents [1]. Finally, some analytical procedures to determine
in vivo protein-protein interactions (such as the tandem
affinity purification) are based on the presence in the
model protein of affinity purification tags [15,16], relying
on the assumption that these additional segments do not
dramatically influence the protein’s natural capability to
perform cross-molecular interactions.
Histidine-rich peptides in Biotechnology
Histidine-rich peptides (often H6 but also other peptide
versions, Table 1) are probably the most used protein pur-
ification tags [1]. Being short sequences, His-tags do not
add significant metabolic load to the protein production
process and they can be easily incorporated to the protein
by simple genetic engineering at the upstream level. Since
the interaction between a His-tag and its ligand does not
require any specific conformation, binding is feasible
under either native or denaturing conditions (e.g. urea
8 M or guanidinium hydrochloride 6 M) [17] as well as
under oxidizing or reducing conditions, resulting in high
technological flexibility and easy scalability [18].
Immobilized metal affinity chromatography (IMAC)
[19] is a separation principle based on the differential
and reversible affinity of transition metal ions such as
Zn
2+,C u
2+,N i
2+, and Co
2+ for histidines [20], due to the
coordination bonds formed between metal ions and
amino acid side chains exposed on the protein surface.
Electron-donor atoms (N, S, O) present in the chelating
compounds of the chromatographic support are capable
of coordinating metal ions and forming metal chelates,
which can be bidentate, tridentate, etc., depending on the
number of occupied coordination bonds [21]. Four of the
six coordination sites on the octahedral Ni
2+ center are
occupied by the nitrilotriacetic acid (NTA) ligand, and
the remaining coordination sites are occupied by two of
the six imidazole moieties in the H6-tag. The model in
which the interaction of the metal ion with His-tag
locates in residues n and n+2 of the tag is confirmed by
the fact that IMAC ligands can bind to His-tags consist-
ing of consecutive as well as to alternating histidine
residues.
As the chelating ligand is used to fix the metal to agar-
ose, iminodiacetic acid (IDA) was initially employed and it
is still in use today in many commercial IMAC resins.
This technology was improved by the invention of the
chelating ligand NTA in the 1980s [22].
The amino acid histidine shows the strongest interac-
tion with immobilized metal ion matrices, as electron
donor groups on histidine imidazole ring readily form
coordination bonds with the immobilized metal. In Bia-
core experiments, the dissociation rate of a H6-tagged
protein to Ni-NTA was estimated to be 1 × 10
-6 to 1.4 ×
10
-8 M at pH 7.0-7.4. The same study also showed that
two histidines separated by either one or four other resi-
dues, are the preferred binding motifs [23]. Interestingly,
selection of an optimum tag by a phage-displayed library
showed that tags with only two histidine residues pos-
sessed chromatographic characteristics superior to those
of the most commonly used H6-tag [24]. Adsorption of a
Table 1 Representative examples of His-rich peptides used in biotechnology as affinity tags for protein purification.
Protein Tag
sequence
Position in the
fusion protein
Tag
removal
Use or biological
activity
# of His
residues
Reference or
PDB entry
GFP H6-N1-H6 C No Protein immobilization 12 [35]
N-acetiltransferase (PA4794) GSS-H6 N No Putative antibiotic
resistance protein
6 3KKW
Toxoflavin-degrading enzyme (TxDE) H8 C No Phytotoxin degradation 8 [36]
Affibody HEHEHE N No In vivo imaging 3 [37]
Antibody H6 C No Antibody Against HER3
and EGFR
6 [38]
Low-density lipoprotein receptor-related
protein 6
H8 N No Blood brain barrier
crossing
8 [39]
eEF-2K thioredoxin-
H6
N Yes Modulation of rate of
protein synthesis
6 [40]
Human peripheral cannabinoid receptor
(CB2)
H10 C Yes Intracellular signal
transduction
10 [41]
Serine protease granzyme B (grB) H6 N Yes Apoptosis inducer 6 [42]
Human granulocyte macrophage colony
stimulating factor (hGMCSF)
H6 N Yes Cytokine 6 [43]
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neutral or slightly basic media in which imidazole nitro-
gens in histidine residues are non-protonated. Elution of
the target protein is achieved by protonation, ligand
exchange or extraction of the metal ion by a stronger
chelator, like EDTA.
Histidine-rich peptides in Nanomedicine
In a very different context, histidine-rich peptides are
largely exploited in drug delivery as powerful endosomal
escape agents, by their incorporation into drug-loaded
nanoparticles or polyplexes to be internalized by target
cells through endosome formation. During centripetal
intracellular trafficking, most of the uptake routes con-
verge into endocytic vesicles, where both vehicle and
cargo may become enzymatically degraded when late
endosomes are transformed into lysosomes [25]. Within
endosomes, the imidazole group of histidine, with a pK
around 6.0, gets protonated under the increasingly acid
conditions. This step recruits Cl
- ions with a consequent
osmotic swelling and endosomal cracking (the ‘proton
sponge’ model [26]), which results in the cytoplasmic
release of the nanoparticle and escape from lysosomal
enzymes. Histidine-rich peptides have been incorporated
into polymers, liposomes and proteins (including virus-
like particles, VLPs) (Table 2). In non-viral gene therapy,
such histidine-empowered vehicles show up to almost
10
4-fold transgene expression improvement when com-
pared with their corresponding histidine-lacking, paren-
tal versions [27]. Despite other membrane-active
peptides, poly-histidines remain neutrally charged at
neutral pH, avoiding non specific binding to serum pro-
teins and consequent inactivation of the particle [28].
The number of histidines and their distribution in the
amino acid sequence of the tag determine endosomal
escape efficiency of His-tagged vehicles and nanoparticles.
Lo and Wang [27] showed that the endosomolytic activity
of Tat-H10 fusion peptides could be 10-fold higher than
Tat-H5 and Tat-H20 versions. Also, 10 His residues dis-
tributed at both sides of Tat peptide (C-5H-Tat-5H-C), are
10
2-fold more efficient than its equivalent C-Tat-10H-C.
Although the optimal number of His residues is believed to
be ranging between 5 and 10 (similar to the figures seen in
His-based affinity tags, Table 1), the incorporation of only
one His residue is sufficient to grant membrane-active
properties to a drug delivery system [29]. Interestingly,
although most of His-tags seem to favour intracellular tar-
geting exclusively through proton sponge activities, LAH4
Table 2 Representative examples of His-rich peptides used in nanomedicine as endosomolytic agents.
Type of construct Tag sequence Experimental model # of His
residues
References
pDNA/siRNA +peptide CHK6HC
CH3K3H3C
CH6K3H6C
In vitro, HepG2, COS 7, and CHO cells, 10X more expression
than w/o histidine
2-12 [44]
pDNA + peptide
+lactosylated
polylysine
H5WYG (23 aas;
GLFHAIAHFIHGGWHGLIHGWYG)
In vitro, HepG2, B16 and Rb-1cells, 93-2150X more expression
than control, with serum.
5 [45]
MS2 VLPs-peptide In Hep3B cells mediate endosomal escape that doesn’t occur
without the peptide.
5 [46]
pDNA+ PEG-H5WYG CHO cells; increase expression 2-5 fold. 5 [47]
Lipopeptide + pDNA Lau/PalCK3H2 In vitro, COS 7 cells, similar results to PEI, lipofectamine 2 [48]
pDNA + peptide LAH4 (26 aas;
KKALLALALHHLAHLALHLALALKKA)
In vitro, human hepatocarcinoma cells, 10× more expression
than lipofectamine.
4 [49]
Chitosan-CH + pDNA Chitosan-CH
Chit. KH dendron
In vitro, HEK293 cells, increases expression up to 50-fold over
chitosan alone.
1 [50]
Chit. 4 gen KH
dendron + pDNA
Chitosan dendron improves escape over Chitosan-CH 1 [51]
pDNA + peptide Tat-H10
C-H5-Tat-H5-C
In vitro, in U251, H4, T98G and C6 cell lines, up to 7000-fold
improvement. In vivo, in rat intrastriatum injection.
10 [27]
FuGENE lipid+ peptide
+ pDNA
In vitro in 5 different cell lines, significant improvement over
pDNA+ peptide alone
10 [52]
CM-PLH+PbAE+pDNA Polymer CM-PLH In vitro, in HEK293 and B16-F10 cells, and in vivo, i.v. mice
injection; higher transfection efficiency over PbAE alone
1 [53]
STR-CH2R4H2C
+pDNA
STR-CH2R4H2C In vitro, COS-7 cells, improves lipofectamine levels of
expression.
2 [54]
(KHKHKHKHKK)6-FGF2
+ pDNA
KHKHKHKHKK In vitro, NIH 3T3, T-47D and COS-1 cells; expression is detected
in 15-41% of cells, but not quantitated; no serum.
24 [55]
Abbreviations: aas, amino acids; pDNA, plasmid DNA; PEI, poly (ethylene imine); aas, aminoacids; Lau, lauryl; Pal, palmytoil; chit. 4 gen, chitosan 4 generation; CM-
PLH, carboxymethyl poly (L- histidine); PbAE, poly (b-amino ester); STR, staeroyl; FGF-2, fibroblast growth factor-2.
Ferrer-Miralles et al. Microbial Cell Factories 2011, 10:101
http://www.microbialcellfactories.com/content/10/1/101
Page 3 of 5(KKALLALALHHLAHLALHLALALKKA) is believed to
interact with the endosomal membrane at pH 7, due to its
amphipathic nature, and disrupt its physical integrity upon
subsequent protonation [30].
On the other hand, H6 has been recently found
involved in intermolecular protein-protein interactions,
leading to the self-assembling of C-terminal His-tagged
building blocks into nanoparticles, useful as vehicles in
non viral gene therapy [31,32]. The nature of such orga-
nizing interactions is yet to be completely understood,
and might involve other specific amino acids such argi-
nines. Since the resulting nanoparticles seem to be more
efficient in transgene expression when formed at slightly
acidic pH values [32], its seems reasonable to speculate
that protonated, overhanging H6 tails interact with anio-
nic protein areas of siding building bocks and also with
DNA. A deeper understanding of the interactions pro-
moted by His-rich peptides could offer tools for the
rational engineering of nanoparticle formation and DNA
encapsulation, both issues of critical relevance in biona-
nomedicine [33,34].
Conclusions
Protein production scientists are usually unaware of the
potent biological properties of histidine-rich peptides for
which they are used in nanomedicine (essentially endo-
somal disruption but also cross-molecular electrostatic
interactions), which are activated at acidic pH. The
same (or very similar) His-rich peptides used in affinity
chromatography, incorporated into different type of
nanoparticles (most ranging from H2 to H10, Table 2)
to favour intracellular trafficking in drug delivery [25],
are equally employed as affinity tags for separation and
often not removed after protein purification (Table 1).
These remaining agents might render unexpected pro-
tein behaviour, when exposed to cells or nucleic acids,
and specific measures for control should be implemen-
ted in biological assays when technical obstacles make
His-tag removal inconvenient upon protein purification.
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